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Objective: We sought to compare outcomes with tissue and St Jude Medical
mechanical valves over a 20-year period.
Methods: Valve-related events and overall survival were analyzed in 2533 patients 18
years of age or older undergoing initial aortic, mitral, or combined aortic and mitral
(double) valve replacement with a tissue valve (Hancock, Carpentier-Edwards
porcine, or Carpentier-Edwards pericardial) or a St Jude Medical mechanical valve.
Total follow-up was 13,390 patient-years. There were 666 St Jude Medical aortic
valve replacements, 723 tissue aortic valve replacements, 513 St Jude Medical mitral
valve replacements, 402 tissue mitral valve replacements, 161 St Jude Medical dou-
ble valve replacements, and 68 tissue double valve replacements. The mean age was
68 ± 13.3 years (St Jude Medical valve, 64.5 ± 12.9; tissue valve, 72.0 ± 12.6).
Results: There were no overall differences in survival between tissue and mechani-
cal valves. Multivariable analysis indicated that the type of valve did not affect sur-
vival. Analysis by age less than 65 years or 65 years or older and presence or
absence of coronary disease revealed similar long-term survival in all subgroups.
The risk of hemorrhage was lower in patients receiving tissue aortic valve replace-
ments but was not significantly different in patients receiving mitral valve or dou-
ble valve replacements. Thromboembolism rates were similar for tissue and
mechanical valve recipients. However, reoperation rates were significantly higher in
patients receiving both aortic and mitral tissue valves. The reoperation hazard
increased progressively with time both in patients receiving aortic and in those
receiving mitral tissue valves. Overall valve complications were initially higher
with mechanical aortic valves but not with mechanical mitral valves. However,
valve complication rates later crossed over, with higher rates in tissue valve recipi-
ents after 7 years in patients undergoing mitral valve replacement and 10 years in
those undergoing aortic valve replacement.
Conclusions: Tissue and mechanical valve recipients have similar survival over 20
years of follow-up. The primary tradeoff is an increased risk of hemorrhage in
patients receiving mechanical aortic valve replacements and an increased risk of
late reoperation in all patients receiving tissue valve replacements. The risk of tis-
sue valve reoperation increases progressively with time.
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Treatment options in patients with valvularheart disease have expanded significantly inthe past decade to include procedures like theRoss procedure, homograft aortic and mitralvalves, stentless tissue valves, and morewidespread use of mitral valve repair.
Despite these newer procedures, valve replacement with a
prosthetic mechanical valve or with porcine or pericardial
xenograft valves remains the standard procedure for most
patients with significant valvular heart disease. Although
several randomized studies have examined differences in
outcomes between patients with tissue and mechanical
valves,1,2 in clinical practice valve selection is not random.
Instead, the selection of a type of prosthetic valve is made
primarily on the basis of patient age,3 valve position, patient
comorbidity, and the risks and benefits of anticoagulation.
Significant insights into the performance of tissue and
mechanical prosthetic valves in real-life settings can be
gained by analysis of a large series of patients receiving
these valves. Therefore, the primary purpose of this article
is to provide long-term outcome data on the results of pros-
thetic heart valve replacement, stratifying by valve position
(aortic vs mitral) and type of valve received (tissue vs St
Jude Medical mechanical valve replacement), over a 20-
year period.
Methods
Data on patients undergoing valve replacement at Cedars-Sinai
Medical Center, a private, university-affiliated, tertiary-care med-
ical center, have been prospectively entered into a computerized
database since 1969. Patients are mailed annual questionnaires,
and those reporting possible events are contacted by a research
nurse. If a questionnaire is not returned, a protocol of repeat mail-
ings followed by telephone calls to the patient or his or her physi-
cian is followed. The National Death Index is queried for patients
whose status cannot be determined. The percentage of patients
classified as lost to follow-up was 2.6% (66/2533). However,
another 3.6% (92/2533) of patients are in the midst of the follow-
up protocol, and some of these may eventually be classified as lost
to follow-up. The recommendations of The American Association
for Thoracic Surgery and Society of Thoracic Surgeons for report-
ing valve-related morbidity and mortality4 were used as guidelines
to analyze patient outcomes. However, operative mortality in this
study was defined to include all deaths occurring during the hospi-
talization for the operation or within 30 days of the operation.
Deaths within 30 days of reoperation on an operated valve were
included as valve-related deaths and as valve complications.
Patient Selection
Patients over the age of 18 years who had either a porcine or peri-
cardial tissue valve or St Jude Medical bileaflet mechanical valve
(St Jude Medical, Inc, St Paul, Minn) implanted in the mitral or
aortic positions were included in this study. The analysis was
restricted to patients operated on during or after 1976. Tissue valve
recipients received either a standard (models 242 [aortic] or 342
[mitral]) or modified-orifice aortic (model 250H) Hancock porcine
valve (Medtronic, Inc, Minneapolis, Minn) or a Carpentier-
Edwards porcine (model 2625 [aortic] or model 6625 [mitral]) or
Carpentier-Edwards bovine pericardial aortic valve (model 2700)
(Edwards Lifesciences Corporation, Irvine, Calif). Patients were
excluded if they received homografts or a combination of both
porcine and mechanical valves or if they had any prior valve
replacement.
Postoperative Management
Patients with mechanical valves were started on a regimen of war-
farin after the operations. Before 1987, warfarin was adjusted to
maintain the prothrombin time (PT) ratio (patient PT/control PT)
at 1.5 to 2.5 times the control value. From 1987 to 1992, the PT
ratio was maintained at 1.5 to 2.0 times the control value. Since
1992, warfarin has been titrated to a target international normal-
ized ratio of 2.5 to 3.5. Patients with mitral tissue valves routinely
received warfarin for 3 months after the operation. Before 1992,
the dose was adjusted to 1.3 to 1.5 times the control value and sub-
sequently adjusted to an international normalized ratio of 2.0 to
3.0. Warfarin therapy in patients with aortic tissue valves was
optional and determined by factors such as patient age and risk fac-
tors for bleeding or thromboembolism. Tissue valve recipients
received long-term aspirin (325 mg orally each day) postopera-
tively once warfarin was discontinued. Management of anticoagu-
lation after hospital discharge was performed by the patient’s own
physician but generally followed these guidelines.
Statistical Methods
Comparisons between continuous variables were made by
means of t tests or analysis of variance as appropriate.
Comparisons between categorical variables were made by the
Fisher exact test or the χ2 test. All baseline factors that differed
between tissue and mechanical valve groups were used to test
whether valve type was predictive of overall survival after
adjusting for baseline differences in risk factors. A stepwise Cox
proportional hazards regression analysis was used to select a set
of covariates predictive of survival by using a P-to-enter value of
.10. The final covariate model was then compared with the same
model plus valve type. Valve type was considered predictive of
survival if the likelihood ratio test was significant at the .05
level. Survival was estimated by using actuarial life-table meth-
ods. Survival curve plots in Figures 1 to 3, 5, and 6 are stopped
when the population is less than 8 patients. Because of the small
number of double valve recipients, the survival analysis and Cox
multivariable analyses were only performed in the patients
receiving aortic and mitral valve replacements. However, lin-
earized event rates are presented for the patients receiving dou-
ble valve replacements.
In addition to standard Kaplan-Meier life-table analysis, reop-
eration rates were also analyzed by the actual or cumulative inci-
dence method.5 This technique provides an answer to the follow-
ing question: What proportion of the patients will require
reoperation before they die? We have described our procedure for
calculating actual reoperation rates previously.6
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TABLE 1. Preoperative patient characteristics
Mechanical Tissue All P value
No. 1340 1193 2533
Age (y) 64.5 ± 12.9 72.0 ± 12.6 68.0 ± 13.3 .0001
Female sex (%) 49.0 39.8 44.7 <.001
NYHA class IV (%) 37.8 40.9 39.3 .15
(n = 1108) (n = 995) (n = 2103)
Coronary artery disease (%) 50.2 61.6 55.6 .001
Diabetes (%) 14.1 14.6 14.3 .78
Prior MI (%) 19.3 20.0 19.7 .82
Ejection fraction (%) 54.0 ± 14.7 53.0 ± 15.2 53.5 ± 15.0 .21
(n = 573) (n = 636) (n = 1209)
Operative mortality (%) 7.9 9.8 8.8 .09
CABG (%) 44.1 55.8 49.6 .001
Values are given as means ± SD where shown. NYHA, New York Heart Association; CABG, coronary artery bypass grafting; MI, myocardial infarction, NS,
not significant (P > .2).
Figure 1. Freedom from embolism for tissue and St Jude Medical valves. A, Aortic valve embolism data; B, mitral
valve embolism data. The P value compares tissue and mechanical valve embolism rates. The numbers below the
figure are the numbers of patients at risk at the beginning of each time period. NS, Not significant.
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TABLE 2. Linearized event rates
Aortic Mitral Double
Mechanical Tissue Mechanical Tissue Mechanical Tissue
No. 666 723 513 402 161 68
Patient-years 3881 3387 2662 2205 920 336
Endocarditis 0.3% (0.17-0.56) 0.6% (0.32-0.86) 0.3% (0.14-0.62) 0.5% (0.26-0.92) 0.4% (0.14-1.19) 2.4% (1.11-4.81)
Hemorrhage 2.0% (1.6-2.5) 0.7% (0.44-1.0) 1.9% (1.4-2.5) 1.5% (1.0-2.1) 3.2% (2.1-4.4) 2.1% (0.9-4.4)
Valve thrombosis 0.3% (0.13-0.49) 0.0% (0.0-0.14) 0.2% (0.05-0.41) 0.05% (0.002-0.29) 0.2% (0.04-0.87) 0.0% (0.03-1.4)
Embolism 2.5% (2.1-3.1) 2.1% (2.7-3.7) 2.9% (2.3-3.6) 2.5% (1.9-3.3) 3.5% (2.4-4.9) 2.1% (0.9-4.4)
Thrombosis + embolism 2.8% (2.3-3.4) 2.1% (1.7-2.7) 3.0% (2.4-3.7) 2.5% (1.9-3.3) 3.7% (2.6-5.2) 2.1% (0.9-4.4)
All valve complications 5.2% (4.5-5.9) 4.8% (4.1-5.6) 5.6% (4.8-6.6) 7.4% (6.3-8.5) 7.8% (6.2-9.8) 8.6% (5.9-12.3)
Linearized event rates are obtained by dividing the number of events by the total number of patient-years of follow-up. Percentages represent events per
100 patient-years of follow-up or the percentage of events per patient-year. Numbers in parentheses are 95% confidence intervals. All valve complications
includes endocarditis, structural failure, reoperation, hemorrhage, thrombosis, embolism, pannus formation, perivalvular leak, hemolysis, and erosion.
Figure 2. Freedom from hemorrhage comparing tissue and St Jude Medical valves stratified by valve position. A,
Aortic hemorrhage rates; B, mitral hemorrhage rates. NS, Not significant.
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In the comparison of valve complications, the survival curves
for the tissue and mechanical valves cross over each other, com-
plicating the analysis of statistical significance. Therefore, 2 tests
of statistical significance are presented for these event rates, both
calculated with BMDP 2L (BMDP Software, Los Angeles, Calif).7
The first, the Generalized Wilcoxon-Breslow (Breslow) statistic,
weights early events to a greater extent and will therefore be more
sensitive to early divergence of the valve event curves. The second
test, the Generalized Savage (Mantel-Cox), is similar to the log-
rank test and weights early and late events equally.
Results
Patient Characteristics
Basic preoperative patient characteristics are presented in
Table 1 stratified by valve type. Mechanical valve recipients
were younger than tissue valve recipients (P = .0001) and more
often female. Patients receiving tissue and mechanical valves
also differed in the cause of valve disease. Patients with papil-
lary muscle infarction or ischemia were more likely to receive
mechanical valves than porcine valves (P = .0006). However,
degenerative aortic valve disease was the most common cause
for both tissue and mechanical aortic valve replacement.
Operative characteristics, including frequency of concur-
rent coronary bypass operations and operative mortality, are
also summarized in Table 1. Minimal differences were seen
in operative mortality between valve types (9.8% for tissue
valves vs 7.8% for mechanical valves, P = .09), but mortal-
ity did differ significantly by valve position (6.1% for aortic
valves vs 11.8% for mitral valves, P = .001).
Figure 3. Actuarial and actual freedom from reoperation for tissue and mechanical valves categorized by age. The
P values refer to the comparison of the actuarial tissue and mechanical data. A, Aortic tissue valve recipients; B,
mitral tissue valve recipients.
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Valve-Related Complications
The 2 most common and most clinically significant long-term
complications of valve replacement are embolic events and
hemorrhage. There were no significant differences in embolic
events for either the aortic or the mitral tissue and mechanical
valve recipients (Figure 1, A and B). At 15 years, between 71%
and 75% of all patients were free of embolic events after tis-
sue and mechanical valve replacement, respectively, regard-
less of valve position. The linearized rates of valve-related
events are shown in Table 2 for aortic, mitral, and double valve
recipients. The overall rate of in situ valve thrombosis was
0.21% per year for mechanical valves and 0.02% per year for
tissue valves. The overall linearized embolism rate was 2.3%
per year for all tissue valves and 2.8% per year for the St Jude
Medical mechanical valves.
Major hemorrhage occurred less frequently than embol-
ic events. The linearized hemorrhage rate for the patients
receiving St Jude Medical valves was 2.1% compared with
1.1% for those receiving tissue valves. As shown in Figure
Surgery for Acquired Cardiovascular Disease Khan et al
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Figure 4. Annual risk (hazard) of undergoing valve reoperation. A, Aortic tissue valve recipients; B, mitral tissue
valve recipients.
A
B
TABLE 3. Actual reoperation percentages
Mechanical Tissue
(actual rate ± SE) (actual rate ± SE)
Aortic
5 y 0.99% ± 0.44% (n = 506) 1.9% ± 0.68% (n = 412)
10 y 1.3% ± 0.62% (n = 319) 8.4% ± 1.8% (n = 249)
15 y 1.4% ± 0.97% (n = 145) 21.2% ± 3.2% (n = 165)
Mitral
5 y 2.0% ± 0.71% (n = 393) 1.8% ± 0.73% (n = 334)
10 y 2.5% ± 0.93% (n = 280) 12.3% ± 2.0% (n = 277)
15 y 2.94% ± 1.45% (n = 136) 22.3% ± 2.9% (n = 211)
Aortic valve recipients ≥65 y
5 y 1.2% ± 0.59% (n = 336) 1.3% ± 0.63% (n = 313)
10 y 1.9% ± 0.95% (n = 209) 5.8% ± 1.9% (n = 156)
15 y 2.1% ± 1.5% (n = 96) 10.8% ± 3.4% (n = 83)
Mitral valve recipients ≥65 y
5 y 1.4% ± 0.84% (n = 204) 1.5% ± 0.83% (n = 206)
10 y 1.4% ± 0.96% (n = 147) 7.6% ± 2.1% (n = 159)
15 y 1.4% ± 1.4% (n = 70) 14.4% ± 3.6% (n = 97)
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2, A, hemorrhage was more common in aortic mechanical
valve recipients (P < .001). However, among the mitral
valve recipients (Figure 2, B) the frequency of hemorrhage
was similar in those receiving tissue and mechanical valves.
At 15 years, 86% and 85% of mitral tissue and mechanical
valve recipients, respectively, were free of hemorrhage.
Hemorrhage at 15 years was nearly identical in the mechan-
ical aortic valve recipients, the mitral tissue valve recipients,
and the mitral mechanical valve recipients (freedom from
hemorrhage of 85%, 85%, and 86%, respectively).
Other valve complications were less common. No struc-
tural valve failure occurred in the St Jude Medical valve
recipients (7463 patient-years of exposure). However, 107
of the tissue valve recipients had documented structural
valve failure (5928 patient-years). Perivalvular leak
occurred in 13 mechanical valve recipients and in 6 tissue
valve recipients. Significant hemolysis occurred in 3 of the
St Jude Medical valve recipients (linearized rate, 0.04% per
year) but not in any of the tissue valve recipients.
Endocarditis occurred in 61 patients overall, 24 receiving
Figure 5. Survival stratified by patient age. A, Aortic tissue and St Jude Medical valve recipients; B, mitral tissue
and St Jude Medical valve recipients. NS, Not significant.
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from reoperation is graphed in Figure 3, A and B, and also
listed in Table 3. At 5, 10, and 15 years, 1.45%, 1.75%, and
1.82% of mechanical valve recipients had actually under-
gone reoperation. However, in the tissue valve recipients, at
5, 10, and 15 years 1.89%, 10.5%, and 21.4%, respectively,
had required reoperation. Thus, although at 5 years actual
reoperation rates were similar, by 10 and 15 years there
were clear differences in actual reoperation rates between
tissue and mechanical valves.
Survival Analysis
Although survival was better for mechanical valve recipients
overall (P = .002) and for aortic (P = .02) and mitral (P = .03)
valves when analyzed separately, tissue valve recipients were
on average more than 7 years older. After grouping patients
on the basis of age and valve position, mortality was similar
for the tissue and mechanical valve recipients who received
either an aortic or mitral valve (Figure 5, A and B). However,
the mitral mechanical valve recipients under the age of 65
years (Figure 5, B) had a slightly better survival (borderline
significance) than the tissue valve recipients (15-year sur-
vival, 51% ± 5.3% vs 32% ± 5.4%, respectively; P = .10,
Breslow; P = .02, Mantel-Cox). No differences were seen in
the aortic valve recipients (Figure 5, A). Survival curves were
also analyzed by stratifying patients with coronary artery
disease. No significant differences in survival were seen
between tissue and mechanical valves after stratifying by the
presence or absence of coronary artery disease. Analysis of
valve-related mortality (including deaths caused by hemor-
rhage and thromboembolism and deaths within 30 days of
reoperation) revealed no differences in survival for either
aortic or mitral valve recipients.
Multivariable Survival Analysis
A Cox multivariable analysis was performed to adjust for
differences in the baseline patient characteristics between
the tissue and mechanical valve groups. Variables consid-
ered for inclusion were those found to differ significantly
between the tissue and mechanical valve recipients in the
univariate analysis. These variables included patient age,
sex, type of valve (tissue or mechanical), presence of coro-
nary disease, and New York Heart Association class IV sta-
tus. In addition, diabetes was included in the models,
although it was not a significant univariate predictor.
Initially, the aortic and mitral valve recipients were analyzed
together along with terms testing for interactions between
risk factors and valve position. This revealed significant
interactions between the presence of coronary disease and
valve position (P = .03) and between age and valve position
(P < .001). Therefore, the Cox model analyses were then
conducted separately for the aortic and mitral valve recipi-
ents, and the results are shown in Table 4. The final Cox
model indicated that age, New York Heart Association class
Surgery for Acquired Cardiovascular Disease Khan et al
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mechanical valves and 37 receiving tissue mitral valves.
Erosion (left ventricular rupture) occurred infrequently: 4
mechanical and 6 tissue valve recipients had erosion, all
early after the operation and most in the setting of a recent
acute myocardial infarction.8 Pannus formation (tissue
ingrowth) was only reported in 2 mechanical valve recipi-
ents, with a linearized rate of 0.027% for mechanical valve
recipients and 0% for tissue valve recipients.
Reoperation
As would be expected, actuarial reoperation rates were sig-
nificantly higher for tissue valve recipients (Figure 3).
Examination of these curves reveals similar freedom from
reoperation for tissue and mechanical valves until approxi-
mately 7 years after the operation, when the curves rapidly
begin to diverge. As Figure 4, A and B, demonstrate, the
annual risk (hazard) of undergoing reoperation increases
progressively with time for the tissue valves. For both aortic
and mitral tissue valves, the hazard is low until approxi-
mately 6 years and then rises at a progressively faster rate.
Trend analysis of the hazard function for tissue valve
reoperation between 6 months and 19 years reveals a signif-
icant trend for the hazard to rise progressively over time
(correlation of 0.91, P < .01) for the combined aortic and
mitral valve replacement data, indicating that the risk of
reoperation does not level off but progressively increases the
longer a patient has had a tissue valve implanted. As can be
seen by comparing panels A and B of Figure 4, there are 2
effects driving tissue valve reoperation: (1) a valve position
effect in which mitral valve reoperation rates are about
twice as high as those for aortic valves and (2) a progres-
sively increasing risk of tissue valve failure with time that
appears to be intrinsic to tissue valves.
Reoperation rates were also analyzed by using the actual
or cumulative method. This technique provides an answer to
the following question: What proportion of the patients will
require reoperation before they die? The actual freedom
TABLE 4. Multivariable analysis of survival
Hazard ratio P value
Aortic (n = 1114)
Age (decade)* 1.50 (1.37-1.65) <.001
NYHA class IV 1.65 (1.40-2.03) <.001
Diabetes 1.68 (1.31-2.07) <.001
Mitral (n = 785)
Age (decade) 1.40 (1.26-1.56) <.001
NYHA class IV 1.97 (1.40-2.03) <.001
Diabetes 1.41 (1.09-1.81) <.01
Coronary disease 1.58 (1.28-1.97) <.001
Values are given as hazard (95% confidence intervals). NYHA, New York
Heart Association.
*Age was analyzed as a continuous variable. The coefficient represents
the increase in risk per additional decade of age.
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IV status, and diabetes mellitus were significant predictors
of survival for both the aortic and mitral valve recipients.
Coronary disease was a significant predictor only for the
mitral valve recipients. Importantly, tissue or mechanical
valve type was not a significant predictor of survival in
either the combined analysis or in the separate aortic or
mitral analysis. The type of tissue valve implanted (porcine
vs pericardial) and the type of porcine valve implanted
(Carpentier-Edwards porcine vs Hancock porcine) did not
affect survival.
Causes of Death
A total of 1132 deaths occurred during follow-up, 564 in the
mechanical valve recipients and 568 in the tissue valve
recipients. In 128 patients the cause of death was missing or
unclassified. Of 1004 patients with an identified cause of
Figure 6. Freedom from all valve complications, including valve thrombosis, embolism, hemorrhage, perivalvular
leak, structural failure, endocarditis, pannus formation, annular erosion, reoperation, valve-related death, death
within 30 days of reoperation, valve failure, and hemolysis. A, Aortic valve recipients; B, mitral valve recipients.
Two statistical tests are shown; the Wilcoxon-Breslow test gives greater weight to early events, and the Mantel-
Cox test weights early and late events equally. NS, Not significant.
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death, cardiac death accounted for 667 (66.4%) and noncar-
diac death for 337 (33.6%) patient deaths. Deaths that were
judged to be valve related occurred in 174 patients (86
mechanical and 88 tissue), and sudden unexpected or unex-
plained death occurred in an additional 78 patients (40
mechanical and 38 tissue). Nonvalvular cardiac causes
accounted for 45% (254/564) of mechanical valve–related
deaths and 42% (239/568) of tissue valve–related deaths
overall (P = .35). Valve-related deaths accounted for only
15.2% (86/564) of mechanical valve–related deaths and
15.5% (88/568) of tissue valve–related deaths (P = .97). The
highest proportion of valve-related deaths were in the dou-
ble valve recipients but still accounted for only 22% (17/77)
of mechanical valve–related deaths and 26% (11/42) of tis-
sue valve–related deaths in these patients (P = .78).
Overall Valve Complications
The analysis of all valve complications is plotted in Figure 6,
A and B, and includes valve thrombosis, embolism, hemor-
rhage, perivalvular leak, structural failure, endocarditis, pan-
nus formation, annular erosion, reoperation, valve-related
death, death within 30 days of reoperation, valve failure, and
hemolysis. Early valve complication rates were initially
slightly higher for mechanical valves in both the aortic and
mitral positions, although the differences were of borderline
significance only for the aortic valves (P = .03, Breslow). This
early difference is probably the result of the higher hemor-
rhage rate seen in the mechanical aortic valve recipients.
However, the valve complication curves in Figure 6
demonstrate a crossover point for both the aortic and mitral
valve recipients. For the mitral valve recipients, this
crossover point occurs at approximately 7 to 8 years, and for
the aortic valve recipients, it occurs at 10 years. Before this
point, freedom from valve complications is better for tissue
valve recipients than for mechanical valve recipients,
whereas after the crossover point, freedom from complica-
tions is better for mechanical valve recipients. Statistical
testing confirmed that late complication rates were signifi-
cantly higher for the mitral tissue valve recipients (P = .04,
Mantel Cox statistic). This crossover likely occurs as the
rate of tissue valve reoperation accelerates and outweighs
the constant ongoing risk of anticoagulant-related hemor-
rhage with mechanical valves.
Discussion
This study demonstrates similar outcomes in tissue and
mechanical valve recipients over a 20-year period. The small
difference in survival of younger (<65 year of age) patients
with mechanical mitral valves was of borderline significance
and disappeared after adjustment for age. The risk of
embolism did not differ between tissue and mechanical
valves for either the aortic or mitral valve recipients. The pri-
mary difference in outcomes seen between these valve types
was a higher risk of hemorrhage in the aortic mechanical
valve recipients and a higher risk of structural failure in all
tissue valve recipients. The crossover point in overall valve
complications between tissue and mechanical valves is logi-
cal and follows from the progressively increasing rate of tis-
sue valve reoperation balanced against a constant higher risk
of hemorrhage in the mechanical valve recipients. The later
crossover point of aortic valve recipients compared with that
of mitral valve recipients is consistent with the higher rate of
mitral valve recipient reoperation.
One of the most interesting observations in this study is
the data set on the annual risk (hazard) of tissue valve reop-
eration. Analysis of the hazard (annualized rate) of tissue
valve reoperation suggests that the risk of valve reoperation
begins to rise in years 6 to 8 and increases progressively
with time. No leveling off or reduction in risk of tissue valve
failure was seen, and in fact, the plots of the hazard func-
tions suggest a steady acceleration in the risk of tissue valve
failure with time. These data provide a real-world estimate
of the performance of these commonly implanted heart
valves in a relatively elderly general population and demon-
strate that the choice of a tissue or mechanical valve is pri-
marily a balance of the risk of anticoagulation against the
risk of reoperation.
Comparison of the linearized rates of hemorrhage and
embolism for our St Jude Medical valve recipients with the
literature demonstrates that our findings are consistent with
series from the United States reported by Kratz,9
Fernandez,10 and their colleagues and with the hemorrhage
rates reported by Ibrahim and coworkers11 from Ireland.
However, our embolism rates are higher than those from
Japan reported by Aoyagi,12 Nakano,13 and their associates
and from Arom and coworkers14 in the United States and
Baudet and colleagues15 in France. The higher rates of
embolic events may be related to the greater age of our
patients compared with those in these other series. For
example, our overall mean patient age was 68 ± 13 years,
whereas the mean patient ages in the series from Japan by
Aoyagi and colleagues12 and Nakano and coworkers13 were
52 and 48 years, respectively. Our previous data suggest that
the variation in thromboembolism rates in prosthetic valve
recipients is strongly associated with nonvalvular patient
risk factors for stroke, such as age and the presence of coro-
nary disease.16
The embolism rates in our tissue valve recipient popula-
tion are also somewhat higher than those observed by other
authors, whereas our reoperation rates are lower. Fann and
associates17 reported freedom from thromboembolism at 15
years of 87% for aortic valve recipients and 77% for mitral
valve recipients compared with that in our series, in which
70% of aortic valve recipients and 73% of mitral valve
recipients were free of embolism. However, the average
patient ages in this series were 60 and 58 years for aortic
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and mitral valve recipients, respectively, compared with an
average age for tissue valve recipients in our series of 72
years. As might be expected from this difference in patient
age, freedom from reoperation was higher in our series.
Thus, at 15 years, freedom from reoperation in the series of
Fann and colleagues was 53% for aortic valve recipients and
33% for mitral valve recipients compared with 67% for aor-
tic valve recipients and 52% for mitral valve recipients in
our series. In a series by Jones and coworkers,18 74% of aor-
tic valve recipients and 61% of mitral valve recipients were
free of reoperation for all causes at 10 years. Jamieson and
colleagues,19 in a series of 1181 patients with Carpentier-
Edwards standard porcine valves, reported freedom from
structural failure of 40.6% in aortic valve recipients and
8.5% in mitral valve recipients compared with our freedom
from reoperation of 48.9% for aortic valve recipients and
26.0% for mitral valve recipients. These figures are not
exactly comparable because we are reporting freedom from
reoperation compared with freedom from structural failure
and the population of Jamieson and coworkers is much
younger (mean age of 57.9 years compared with our mean
age of 68 years). In a somewhat older series of 1007 patients
(all over 70 years; mean age, 75.6 years) receiving tissue
valves, Pupello and colleagues20 reported a better freedom
from structural failure: 80.4% at 15 years for aortic valve
recipients and 84.6% for mitral valve recipients. Thus, our
tissue valve reoperation rates fit between published series
with younger and older patient populations.
The rates of other valve complications in our series are
comparable with those reported by other authors. For exam-
ple, the endocarditis rate was 0.3% per year for mechanical
valve recipients in our series for both aortic and mitral valve
recipients, which is similar to the 0.3% reported by Nitter-
Hauge and Abdelnoor21 in 1104 patients with the Medtronic
Hall prosthesis and the 0.3% reported for all patients by
Ibrahim and colleagues.11 The rate of valve thrombosis was
0.3% and 0.2% in our series for aortic and mitral valve
recipients compared with 0.1% for aortic and mitral valve
recipients in the series by Nitter-Hauge and Abdelnoor.21
Limitations
Although our conclusions regarding the relative limitations
of mechanical and tissue valves agree with conventional
thinking about the relative risks of hemorrhage and reoper-
ation, several limitations must be kept in mind. First, our
study was not a randomized comparison of tissue and St
Jude Medical valves, and this creates the potential for bias
in valve selection. Although we have tried to adjust for these
differences in the survival analysis by using multivariable
methods, there may be variables that were not adjusted for
because they were not measured. However, the variables
analyzed here completely explain any potential differences
in survival, suggesting that other variables would not add to
our understanding of survival differences. A second limita-
tion is the use of standard porcine and pericardial valves.
Other tissue valves, such as stentless valves and aortic
homografts, or the Ross procedure may demonstrate differ-
ent outcomes and event rates. We have also been unable to
differentiate between major and minor thromboembolic
events, which is an intrinsic limitation of our database. A
final possible limitation is the combination of multiple types
of tissue valves in the analysis: the Carpentier-Edwards
porcine valve, the Hancock standard or modified orifice
valves, and the Carpentier-Edwards pericardial valve.
However, a recently published randomized trial with 1369
patient-years of follow-up demonstrated that there are no
significant differences in durability between the Hancock
and Carpentier-Edwards porcine valves.22 It remains less
clear whether there are differences in event rates and dura-
bility between standard porcine valves and the Carpentier-
Edwards pericardial valve. However, it is important to point
out that because the Carpentier-Edwards pericardial valve
has only been used at our institution since 1992, the accel-
eration of the risk of valve reoperation at 7 to 10 years
observed in the overall tissue valve group does not neces-
sarily apply to this valve.
In summary, survival was similar after adjustment for
risk factors with tissue and St Jude Medical mechanical
valves in both aortic and mitral valve recipients. An increase
in hemorrhage was seen in the aortic mechanical valve
recipients, but embolism rates did not differ between valve
types. Reoperation rates were significantly higher in all tis-
sue valve recipients and appeared to accelerate after about
10 years. These data suggest that outcomes after tissue and
mechanical valve replacement are similar, with the primary
tradeoff being the risks of anticoagulant-related hemorrhage
in mechanical aortic valve recipients versus the risk of reop-
eration after 8 to 10 years in tissue valve recipients.
We thank Dr Timothy Denton and Dr Richard Gray, without
whose help this article would not have been possible.
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Discussion
Dr W. R. Eric Jamieson (Vancouver, British Columbia,
Canada). Dr Trento, this is a very important contribution because we
now have to begin to identify the performance of biologic mechani-
cal prostheses up to at least 15 years and maybe on to 20 years in our
decision making with regard to what we offer and recommend to our
patients. What you have really shown is that valve-related complica-
tions, reoperation, and survival are all very important points. Your
summary slide does show that there is some preponderance of per-
formance in aortic position with regard to less hemorrhage and with
regard to putting in bioprostheses versus mechanical prostheses. In
the mitral position there is not that major differentiation.
I have a number of questions for you, and the first concerns
how you handled thromboembolism. You have not defined it. Is it
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all major events or both major and minor events, and did you
include the events that occurred in the first 30 days?
Dr Trento. We included all events, both major and minor,
including the first 30 days. 
Dr Jamieson. Is there a difference between the major events
that occurred with the mechanical prosthesis versus those occur-
ring with the biologic prosthesis?
Dr Trento. We have not analyzed these differences. We had
about 250 episodes of hemorrhage, but we did not analyze the
major and minor hemorrhages.
Dr Jamieson. There is another point with relation to throm-
boembolism. In your article you note a number of thrombosis
cases—I think 6 in the mechanical series and 4 in the tissue series.
Could you elaborate on those? Were they aortic or mitral, and how
were they managed?
Dr Trento. I do not remember whether they were aortic or
mitral. Now we manage valve thrombosis by infusion of streptok-
inase, and that has been quite successful in our practice.
Dr Jamieson. I was interested because of the 6 cases in the
mechanical series and the 4 cases in the biologic series. We have
seen similar experience in the mechanical and mitral valves but not
in the biologic valves.
You discussed a number of cases as annular erosion or left ven-
tricular rupture. Were these early cases or late cases? Were they
atrioventricular groove disruptions?
Dr Trento. The way they were classified is affected by the fact
that this is a 20-year data collection. Annular erosion and ventric-
ular disruption are the same thing, the typical atrioventricular
groove disruption.
Dr Jamieson. Did you see any cases in which the strut of the
prosthesis eroded the ventricular wall? We saw this early in our
experience if we inserted too large a mitral prosthesis, depending
on the orientation.
Dr Trento. I think that all these events were early events. They
were perioperative events.
Dr Jamieson. In your article you relate to the management of
ischemic disease and muscle disruption, in which you implant a
mechanical prosthesis in these patients. My concern is whether
these patients have enough comorbidity to offer them a biologic
prosthesis or whether these patients really do very well after mus-
cle disruption in a mechanical prosthesis.
Dr Trento. This is obviously a process that may have changed
over time in our practice. There have probably been about 15 sur-
geons over a period of 20 years performing these procedures. At
the present time, it is the surgeon’s decision as to what type of
prosthesis to use in the presence of acute myocardial necrosis, and
therefore we do not have a generalized and unified approach to this
type of situation.
Dr Jamieson. Your article deals also with the concept of actu-
al freedom versus actuarial freedom. A proponent of that is Dr
Gary Grunkemeier, who is a member of our Association and who
is here. One of the ways we are starting to look at our data is the
actuarial freedom from mortality and reoperation but also perma-
nent impairment or permanent morbidity to the patients. I know
you did not analyze this. You did analyze it for reoperation but with
regard to thromboembolism. Do you think that looking at the con-
cept of actual freedom—which is really better information for our
patients—would be more appropriate?
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article whether this influenced your current practice. What is your
recommended practice?
Dr Trento. I think that this article came out to be quite neu-
tral, and we did not mean it in this way. We are open minded,
and after reviewing the article, I think that each of you can prob-
ably arrive at different conclusions. I can only tell you my per-
sonal approach. Patients over age 65 years get a porcine aortic
biologic prosthesis. Patients under age 60 years get either a
mechanical prosthesis or some other type of procedure. For
mitral valve recipients, patients over age 60 years with coronary
artery disease probably get a biologic prosthesis, but that again
is my preference. I think there are 8 surgeons in our group, and
each of them has his own approach.
Dr Jamieson. Our current approach, according to a recent
analysis of our data using the actuarial methodology, is that in the
mitral position we place a bioprosthesis for patients over 70 years
unless they have extensive comorbid disease. Patients under 70
years receive a mechanical prosthesis if the valve is not being
repaired. In the aortic position, using actuarial methodology, our
freedom from structural failure in patients over 70 years is 95% at
15 years, and in those patients between 61 and 70 years, the actu-
arial freedom is 88% at 15 years. Of course, below that you have
the role of stentless prosthesis, autografts, and homografts.
Dr Trento. It is an interesting concept to look at the actual free-
dom from debilitating events and something that we should proba-
bly do. The concept of actual versus actuarial is a difficult concept
to grasp. The actuarial concept looks at the valve and tells us how
long the valve is going to last. The actual concept looks at the patient
and tells us what the chance is for this patient to have a valve reop-
eration after 15 years. I think that expanding the actual concept to
complication events other than reoperation may be very interesting.
Dr Jamieson. I have a question related to your reoperative
mortality with regard to biologic prosthesis, specifically with
regard to structural valve deterioration. Has that lessened over the
years? Would you tend to place biologic prostheses in specific
indications as a result?
Dr Trento. I do not think there was a statistical difference in
operative mortality between reoperations and first-time reopera-
tion. The operative mortality was slightly higher. We did 108 reop-
erations. I could not tell whether the incidence of mortality in the
recent reoperations was much better.
Dr Jamieson. In our experience in the past 9 years, our mor-
tality with reoperating on aortic or mitral valves is not different,
and it was approximately 4%.
It would be nice to see further age stratification of your data and
maybe further actuarial analysis, but you did not indicate in your
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